Plomestane

In the modern world, Plomestane has become a topic of increasing interest to a wide spectrum of people. From experts in the field to those who know little about the subject, Plomestane has captured everyone's attention. With the rapid evolution of technology and society, Plomestane has become relevant in various aspects of daily life. In this article, we will explore in depth the complexities and dimensions of Plomestane, analyzing its impact in different areas and offering a comprehensive overview of this intriguing issue.

Plomestane
Clinical data
Other namesMDL-18962; Propargylestrenedione; PED; 10-(2-Propyn-1-yl)estr-4-ene-3,17-dione; 10-Propargylestr-4-ene-3,17-dione
ATC code
  • None
Identifiers
  • 10H-(2-Propynyl)-estr-4-ene-3,17-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H26O2
Molar mass310.437 g·mol−1
3D model (JSmol)
  • O=C4\C=C3/(CC#C)(2CC1(C(=O)CC12CC3)C)CC4
  • InChI=1S/C21H26O2/c1-3-10-21-12-8-15(22)13-14(21)4-5-16-17-6-7-19(23)20(17,2)11-9-18(16)21/h1,13,16-18H,4-12H2,2H3/t16-,17-,18-,20-,21-/m0/s1
  • Key:JKPDEYAOCSQBSZ-OEUJLIAZSA-N

Plomestane (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code name MDL-18962; also known as propargylestrenedione, PED) is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer.[1][2][3][4][5] It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration.[5] However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.[6]

In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties.[5]

See also

References

  1. ^ Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1635. ISBN 978-0-412-46630-4. Retrieved 19 May 2012.
  2. ^ Morton IK, Hall JM (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 227. ISBN 978-0-7514-0499-9. Retrieved 20 May 2012.
  3. ^ Lombardi P (June 1995). "The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds". Current Pharmaceutical Design. 1. Bentham Science Publishers: 23–50 (45). doi:10.2174/1381612801666220524190226. S2CID 249298105. Retrieved 20 May 2012.
  4. ^ Kreider RB, Leutholtz BC, Katch FI, Katch VL (2009). Exercise and Sport Nutrition. Exercise & Sport Nutrition. p. 350. ISBN 978-0-9742965-6-2. Retrieved 20 May 2012.
  5. ^ a b c Kelloff GJ, Lubet RA, Lieberman R, et al. (January 1998). "Aromatase inhibitors as potential cancer chemopreventives". Cancer Epidemiology, Biomarkers & Prevention. 7 (1): 65–78. PMID 9456245.
  6. ^ Avendaño C, Menéndez JC (4 June 2008). Medicinal Chemistry of Anticancer Drugs. Elsevier. p. 69. ISBN 978-0-444-52824-7. Retrieved 20 May 2012.



Stub icon

This article about a steroid is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.